Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Seagen Inc (NQ: SGEN )

170.14 -3.90 (-2.24%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 12, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,794,829
Open 174.00
Bid (Size) 171.00 (1)
Ask (Size) 174.49 (1)
Prev. Close 174.04
Today's Range 164.81 - 176.03
52wk Range 105.43 - 192.79
Shares Outstanding 181,934,500
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Does Merck Finally Have The Fodder It Needs To Buy Seagen?
The final piece ahead of a potential Seagen buyout took place Friday and shares rose. 
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
  This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga

Performance

YTD
+7.79%
+7.79%
1 Month
-4.80%
-4.80%
3 Month
+19.36%
+19.36%
6 Month
+36.65%
+36.65%
1 Year
+9.16%
+9.16%

More News

Read More
Seagen Statement on Outcome of Daiichi Sankyo Arbitration
From Seagen Inc.
Via Business Wire
Seattle Genetics's Return On Capital Employed Overview
Via Benzinga
Seagen Q2 Earnings - Better Than Expected, Mum On M&A, Lifts Outlook
Via Benzinga
Seagen Crushes Quarterly Forecasts With Narrower-Than-Expected Losses
Via Investor's Business Daily
Seagen's Bladder Cancer Trial Data Meets Expectation, Analysts Say
Via Benzinga
Where Seagen Stands With Analysts
Via Benzinga
Recap: Seagen Q2 Earnings
Via Benzinga
Seagen Reports Second Quarter 2022 Financial Results
From Seagen Inc.
Via Business Wire
7 Stocks to Buy on the Dip
Via InvestorPlace
The 3 Best Market Sectors for the Second Half of 2022
Via InvestorPlace
Analyst Ratings for Seagen
Via Benzinga
Earnings Scheduled For July 28, 2022
Via Benzinga
Recap Of Tuesday's Biotech Catalysts - End of The Day Summary
Via Benzinga
Seagen Tips Its Hand In Bladder Cancer, But Is It Enough To Woo Merck?
Via Investor's Business Daily
Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate
Via Benzinga
Alibaba, General Electric And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
Via Benzinga
Seagen Shares Jump On Positive Data From Urothelial Cancer Trial
Via Benzinga
Seagen and Astellas Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer
From Seagen Inc.
Via Business Wire
$1000 Invested In Seagen 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Why Merck's Rumored $40 Billion Seagen Buyout Is On Shaky Ground
Via Investor's Business Daily
This Favorable Sign Appears On Seagen's Chart
Via Benzinga
Why Qudian Shares Jumped Over 40%; Here Are 73 Biggest Movers From Yesterday
Via Benzinga
Check Out What Whales Are Doing With SGEN
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.